Low-fat meal

DRUG2 trials

Sponsors

Hospital Universitari Vall d'Hebron Research Institute, University of Chicago

Conditions

HealthyProstate AdenocarcinomaProstate CancerProstate Cancer MetastaticProstate Neoplasm

Phase 1

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

TerminatedNCT05276492

University of ChicagoProstate Adenocarcinoma, Prostate Cancer, Prostate Cancer Metastatic +1

Start: 2023-01-24End: 2024-11-16Updated: 2025-10-03

Unknown Phase

Effect of Meal Composition on the Responses to Meal Ingestion

CompletedNCT03084276

Hospital Universitari Vall d'Hebron Research InstituteHealthy

Start: 2017-01-16End: 2017-03-21Updated: 2017-04-25